Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

Leukemia

Volumn 26, Issue 6, 2012, Pages 1422-1425

  Spector, M S ^a   Iossifov, I ^a   Kritharis, A ^b,c   He, C ^a   Kolitz, J E ^b,c   Lowe, S W ^a,d   Allen, S L ^b,c  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CYTARABINE; DASATINIB; IDARUBICIN; IMATINIB; IMMUNOGLOBULIN E; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

BETA CHAIN; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG MEGADOSE; EXOME; GENE MUTATION; GENE SEQUENCE; HUMAN; INTRON; LETTER; MAST CELL LEUKEMIA; PRIORITY JOURNAL;

EID: 84862005479     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.354     Document Type: Letter

References (15)

1. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 2006; 6: 218-230. (Pubitemid 43290991)
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625. (Pubitemid 32506768)
3. Ustun C, Deremer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35: 1143-1152.
4. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
5. Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011; 96: 459-463.
6. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz Jr LA, Sjoblom T et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692. (Pubitemid 43376616)
7. Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS One 2007; 2: e203.
8. Hartmann K, Wardelmann E, Ma Y, Merkelbach-Bruse S, Preussner LM, Woolery C et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005; 129: 1042-1046. (Pubitemid 41242694)
9. Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007; 6: 1159-1166. (Pubitemid 46554587)
10. Kraft S, Kinet JP. New developments in FceRI regulation, function and inhibition. Nat Rev Immunol 2007; 7: 365-378. (Pubitemid 46674486)
11. Donnadieu E, Jouvin MH, Rana S, Moffatt MF, Mockford EH, Cookson WO et al. Competing functions encoded in the allergy-associated FceRIbeta gene. Immunity 2003; 18: 665-674. (Pubitemid 36588583)
12. Cruse G, Kaur D, Leyland M, Bradding P. A novel FceRIbeta-chain truncation regulates human mast cell proliferation and survival. FASEB J 2010; 24: 4047-4057.
13. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326-339.
14. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
15. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009; 16: 281-294.